Search results for "SYNERGISM"

showing 10 items of 153 documents

Reaction of melatonin with lipoperoxyl radicals in phospholipid bilayers.

1997

Melatonin, at 5 to 500 microM was incorporated in unilamellar soybean phosphatidylcholine (PC) liposomes, the peroxidation of which was induced by 2,2'-azobis (2-amidinopropane-hydrochloride) (AAPH), and measured as production of conjugated diene lipid hydroperoxides. Concentration as low as 5 and 10 microM were poorly effective in reducing lipid peroxidation. Melatonin at 30 to 500 microM caused short inhibition periods, increasing with, but not linearly related to concentration, with a concurrent net decrease of the propagation rate. The time course of melatonin oxidation, measured as loss of fluorescence, was studied during the AAPH-stimulated peroxidation of soybean PC liposomes, or whe…

Lipid PeroxidesAntioxidantFree Radicalsmedicine.medical_treatmentLipid BilayersPhospholipidPhotochemistryBiochemistryMelatoninLipid peroxidationchemistry.chemical_compoundPhysiology (medical)PhosphatidylcholinemedicineVitamin ETocopherolMelatoninLiposomeVitamin EDrug SynergismFree Radical ScavengersKineticschemistryBiophysicsPhosphatidylcholinesLipid PeroxidationOxidation-Reductionhormones hormone substitutes and hormone antagonistsmedicine.drugFree radical biologymedicine
researchProduct

Anti-inflammatory effects of cinnamon extract and identification of active compounds influencing the TLR2 and TLR4 signaling pathways

2018

Purpose: Inflammatory processes are involved in many diseases. The bark of Cinnamomum verum and its extracts are well known for anti-inflammatory effects, but the underlying active compounds and chemical mechanisms are not yet fully identified. The objective of this study was to elucidate how cinnamon extract, specifically active compounds, and their combinations influence the signaling pathways of inflammation, especially through toll-like receptors TLR2 and TLR4. Methods: Bioassay-guided fractionation was performed for standard ethanolic cinnamon extract using high performance liquid chromatography followed by compound identification in the determined active fractions by high-resolution m…

Lipopolysaccharides0301 basic medicineCinnamomum zeylanicumCell SurvivalTHP-1 Cellsmedicine.drug_classAnti-Inflammatory AgentsPharmacologyMonocytesCinnamic acidAnti-inflammatory03 medical and health scienceschemistry.chemical_compoundNF-KappaB Inhibitor alphamedicineHumansAcroleinPhosphorylationProtein kinase BCinnamyl alcoholbiologyPlant ExtractsChemistryInterleukin-8Cinnamomum verumNF-kappa BDrug SynergismGeneral Medicinebiology.organism_classificationToll-Like Receptor 2Toll-Like Receptor 4IκBα030104 developmental biologyMonoterpenesCymenesPhosphorylationSignal transductionProto-Oncogene Proteins c-aktSignal TransductionFood ScienceFood & Function
researchProduct

Effects of Escherichia coli hemolysin on human monocytes. Cytocidal action and stimulation of interleukin 1 release.

1990

Abstract This study reports on the potent cytocidal and interleukin-1 releasing properties of Escherichia coli hemolysin (ECH) on human monocytes. Nanomolar concentrations of purified ECH (250-2,000 ng/ml) caused rapid and irreversible depletion of cellular ATP to levels below 20% of controls within 60 min. Subcytocidal doses (10-200 ng/ml) of ECH induced rapid release within 60-120 min of large amounts of interleukin 1 beta (IL-1 beta) from cultured monocytes. IL-1 beta release occurred in the presence of actinomycin D and cycloheximide, and was thus probably due to processing and export of intracellular IL-1 beta precursor. Incubation of toxin-producing E. coli at ratios of only 0.3-3 col…

LipopolysaccharidesCell SurvivalStimulationIn Vitro TechniquesBiologyCycloheximidemedicine.disease_causeHemolysin ProteinsMonocytesMicrobiologyHemolysin Proteinschemistry.chemical_compoundAdenosine TriphosphateEscherichia colimedicineHumansEscherichia coliCells CulturedToxinMonokinesMonocyteInterleukinDrug SynergismGeneral Medicinemedicine.anatomical_structurechemistrySecretory RateIntracellularResearch ArticleInterleukin-1Journal of Clinical Investigation
researchProduct

Stimulation of monokine production by lipoteichoic acids

1991

Lipoteichoic acids (LTAs) isolated from bacterial species, including Staphylococcus aureus, Streptococcus pyogenes A, Enterococcus faecalis, Streptococcus pneumoniae, and Listeria monocytogenes, were tested for their ability to stimulate the production of interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor alpha in cultured human monocytes. LTAs from S. aureus and S. pneumoniae failed to induce monokine production when applied in the concentration range of 0.05 to 5.0 micrograms/ml. However, LTAs from several enterococcal species (0.5 to 5 micrograms/ml) induced the release of all three monokines at levels similar to those observed after lipopolysaccharide stimulation. The kinet…

LipopolysaccharidesLipopolysaccharideAcylationBacterial ToxinsImmunologyBiologymedicine.disease_causeMicrobiologyEnterococcus faecalisMicrobiologyHemolysin ProteinsStructure-Activity Relationshipchemistry.chemical_compoundmedicineHumansInterleukin-6Tumor Necrosis Factor-alphaMonocyteDrug Synergismbiology.organism_classificationComplement systemTeichoic AcidsMonokineInfectious Diseasesmedicine.anatomical_structurechemistryStreptococcus pyogenesParasitologyTumor necrosis factor alphaLipoteichoic acidPeptidesInterleukin-1Research ArticleInfection and Immunity
researchProduct

Cytoprotective effects of carotenoids-rich extract from Lycium barbarum L. on the beauvericin-induced cytotoxicity on Caco-2 cells.

2019

Abstract In this work, the cytotoxicity of Beauvericin (BEA), lutein (LUT), zeaxanthin (ZEAX) and goji berries extract (GBE) rich in carotenoids, was investigated, as well as cytoprotective effects of these carotenoids against BEA induced-cytotoxicity on Caco-2 cells. Cytotoxicity was carried out using MTT and protein content (PC) assays during 24 and 48 h of exposure. Only BEA showed cytotoxic effect obtaining a reduction in cell proliferation range from 6.5 to 92.8%. Simultaneous combination of LUT and ZEAX with BEA slightly increased cell proliferation compared to BEA tested alone. LUT, ZEAX and GBE showed cytoprotective effects against cytotoxicity induced by BEA on Caco-2 cells. Pre-tr…

LuteinToxicologyProtective Agents03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyfoodZeaxanthinsDepsipeptidesHumansFood scienceCytotoxicityMycotoxinCarotenoid030304 developmental biologychemistry.chemical_classification0303 health sciencesPlant ExtractsGoji berryLuteinDrug Synergism04 agricultural and veterinary sciencesGeneral MedicineLyciumMycotoxins040401 food scienceCytoprotectionBeauvericinfood.foodZeaxanthinchemistryCytoprotectionFruitCaco-2 CellsFood ScienceFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association
researchProduct

Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition …

2007

The molecular mechanisms behind the anti-neoplastic effects of non-steroidal anti-inflammatory drugs (NSAIDs) are not completely understood and cannot be explained by the inhibition of the cyclooxygenase (COX) enzymes COX-1 and COX-2 alone. We previously reported that both the selective COX-1 inhibitor SC-560 and the selective COX-2 inhibitor CAY10404 exhibit anti-tumor effects in human hepatoma cells. NSAID inhibitors have many COX-independent actions and, among others, the mitogen-activated protein kinase (MAPK) pathways are targets for NSAIDs. Here, we examined the role of MEK/ERK1/2 signaling in the anti-neoplastic effects of both selective COX-1 and COX-2 inhibitors in two human hepato…

MAPK/ERK pathwayCancer ResearchCarcinoma HepatocellularTime FactorsBlotting WesternApoptosisPharmacologyCOX-1 COX-2 NSAIDs MEK1/2 ERK1/2NitrilesButadienesTumor Cells CulturedHumansCyclooxygenase InhibitorsSulfonesEnzyme InhibitorsPhosphorylationProtein kinase ACell ProliferationPharmacologychemistry.chemical_classificationMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase KinasesMitogen-Activated Protein Kinase 3biologyDose-Response Relationship DrugLiver NeoplasmsCytochromes cLong-term potentiationDrug SynergismIsoxazolesFlow CytometryEnzymeOncologychemistryCyclooxygenase 2CaspasesCancer cellbiology.proteinCyclooxygenase 1Molecular MedicineMEK-ERK PathwayPyrazolesDrug Therapy CombinationCyclooxygenaseHepatoma cellCancer biologytherapy
researchProduct

The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells.

2011

Lung cancer is a malignant disease with poor outcome, which has led to a search for new therapeutics. The PI3K/Akt/mTOR and Ras/raf/Erk pathways are key regulators of tumor growth and survival. In the present study, their roles were evaluated by MTT assay, flow cytometry and Western blotting in lung cancer cells. We found that a high efficacy of antitumor activity was shown with GDC-0941 treatment in two gefitinib-resistant non-small cell lung cancer (NSCLC) cell lines, A549 and H460. In addition, H460 cells with activating mutations of PIK3CA were relatively more sensitive to GDC-0941 than A549 cells with wild-type PIK3CA. Furthermore, GDC-0941 was highly efficacious in combination with U0…

MAPK/ERK pathwayCancer ResearchIndazolesLung NeoplasmsApoptosisBiologyBiochemistryPhosphatidylinositol 3-KinasesCarcinoma Non-Small-Cell LungCell Line TumorNitrilesGeneticsmedicineButadienesHumansMolecular BiologyProtein kinase BProtein Kinase InhibitorsPI3K/AKT/mTOR pathwayPhosphoinositide-3 Kinase InhibitorsSulfonamidesOncogeneCell growthMEK inhibitorTOR Serine-Threonine KinasesCancerDrug SynergismCell cyclemedicine.diseaseG1 Phase Cell Cycle Checkpointsrespiratory tract diseasesEnzyme ActivationOncologyCancer researchMolecular MedicineMitogen-Activated Protein KinasesSignal TransductionMolecular medicine reports
researchProduct

Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor ce…

2010

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Celecoxib (Celebrex®) exhibits antitumor effects in human HCC cells, and its mechanism of action is mediated either by its ability to inhibit cyclooxygenase 2 (COX-2) or by a number of various other COX-2 independent effects. Proteasome inhibitors (PIs) can exert cell growth inhibitory and apoptotic effects in different tumor cell types, including HCC cells. The present study examined the interaction between celecoxib and the PI MG132 in two human liver tumor cell lines HepG2 and HA22T/VGH. Our data showed that each inhibitor reduced proliferation and induced apoptosis in a dose-dependen…

MG132TRB3Programmed cell deathLeupeptinsBlotting WesternApoptosisUPRPharmacologyCysteine Proteinase Inhibitorschemistry.chemical_compoundMG132medicineHumansViability assayHCCMolecular BiologyCell ProliferationSettore MED/12 - GastroenterologiaGene knockdownSulfonamidesbiologyCyclooxygenase 2 InhibitorsCell growthReverse Transcriptase Polymerase Chain ReactionDrug SynergismCell BiologyHep G2 CellsCOX-2ER stress responseFlow CytometryapoptosiproteasomechemistryApoptosisCelecoxibSettore BIO/14 - Farmacologiabiology.proteinProteasome inhibitorPyrazolesCyclooxygenaseDevelopmental Biologymedicine.drug
researchProduct

Present and Perspectives of Photoactive Porous Composites Based on Semiconductor Nanocrystals and Metal-Organic Frameworks

2021

This review focuses on the recent developments in synthesis, properties, and applications of a relatively new family of photoactive porous composites, integrated by metal halide perovskite (MHP) nanocrystals and metal-organic frameworks (MOFs). The synergy between the two systems has led to materials (MHP@MOF composites) with new functionalities along with improved properties and phase stability, thus broadening their applications in multiple areas of research such as sensing, light-harvesting solar cells, light-emitting device technology, encryption, and photocatalysis. The state of the art, recent progress, and most promising routes for future research on these photoactive porous composit…

MHP@MOF compositesMaterials sciencePhotoluminescenceperovskitesPharmaceutical ScienceHalideOrganic chemistryphotoactive materialsReviewMOFsAnalytical ChemistryQD241-441NanocrystalChemistry (miscellaneous)synergismDrug DiscoveryPhotocatalysisMolecular MedicineSemiconductor nanocrystalsMetal-organic frameworkphotoluminescencePhysical and Theoretical ChemistryComposite materialPorosityPerovskite (structure)Molecules
researchProduct

Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition

2017

AbstractPurpose: Despite advances in multimodal therapy, neuroblastomas with hemizygous deletion in chromosome 11q (20%–30%) undergo consecutive recurrences with poor outcome. We hypothesized that patients with 11q-loss may share a druggable molecular target(s) that can be exploited for a precision medicine strategy to improve treatment outcome.Experimental Design: SNP arrays were combined with next-generation sequencing (NGS) to precisely define the deleted region in 17 primary 11q-loss neuroblastomas and identify allelic variants in genes relevant for neuroblastoma etiology. We assessed PARP inhibitor olaparib in combination with other chemotherapy medications using both in vitro and in v…

Male0301 basic medicineCancer ResearchDNA repairAntineoplastic AgentsAtaxia Telangiectasia Mutated ProteinsKaplan-Meier EstimatePoly(ADP-ribose) Polymerase InhibitorsBiologyModels BiologicalPolymorphism Single NucleotideImmunophenotypingOlaparibNeuroblastoma03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRecurrenceCell Line TumorNeuroblastomaBiomarkers TumormedicineAnimalsHumansAllelesNeoplasm StagingCisplatinTemozolomideChromosomes Human Pair 11High-Throughput Nucleotide SequencingCancerDrug SynergismPrognosismedicine.diseaseXenograft Model Antitumor AssaysMolecular biologyDisease Models Animal030104 developmental biologyOncologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisPARP inhibitorCancer researchFemaleChromosome DeletionHaploinsufficiencyBiomarkersmedicine.drugClinical Cancer Research
researchProduct